Hartmut Porst
Private Practice of Urology and Andrology
Neuer Jungfernstieg 6a
20354 Hamburg
Germany
Name/email consistency: high
- Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. Porst, H., Brock, G.B., Kula, K., Moncada, I., Montorsi, F., Basson, B.R., Kinchen, K., Aversa, A. J. Androl. (2012)
- Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. Porst, H., Hell-Momeni, K., Büttner, H. Expert. Opin. Pharmacother (2012)
- Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. Porst, H., Glina, S., Ralph, D., Zeigler, H., Wong, D.G., Woodward, B. J. Sex. Med (2010)
- Standards for clinical trials in male sexual dysfunctions. Porst, H., Vardi, Y., Akkus, E., Melman, A., Park, N.C., Seftel, A.D., Teloken, C., Wyllie, M. J. Sex. Med (2010)
- Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. Porst, H., McMahon, C.G., Althof, S.E., Sharlip, I., Bull, S., Aquilina, J.W., Tesfaye, F., Rivas, D.A. J. Sex. Med (2010)
- Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Porst, H., McVary, K.T., Montorsi, F., Sutherland, P., Elion-Mboussa, A., Wolka, A.M., Viktrup, L. Eur. Urol. (2009)
- Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Porst, H., Sandner, P., Ulbrich, E. Curr. Urol. Rep (2008)
- Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. Porst, H., Rajfer, J., Casabé, A., Feldman, R., Ralph, D., Vieiralves, L.F., Esler, A., Wolka, A.M., Klise, S.R. J. Sex. Med (2008)
- Development and validation of the quality of erection questionnaire. Porst, H., Gilbert, C., Collins, S., Huang, X., Symonds, T., Stecher, V., Hvidsten, K. J. Sex. Med (2007)
- The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Porst, H., Montorsi, F., Rosen, R.C., Gaynor, L., Grupe, S., Alexander, J. Eur. Urol. (2007)
- Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Porst, H., Giuliano, F., Glina, S., Ralph, D., Casabé, A.R., Elion-Mboussa, A., Shen, W., Whitaker, J.S. Eur. Urol. (2006)
- Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Porst, H., Sharlip, I.D., Hatzichristou, D., Rubio-Aurioles, E., Gittelman, M., Stancil, B.N., Smith, P.M., Wilkins, H.J., Pommerville, P. Eur. Urol. (2006)
- IC351 (tadalafil, Cialis): update on clinical experience. Porst, H. Int. J. Impot. Res. (2002)
- The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Porst, H., Rosen, R., Padma-Nathan, H., Goldstein, I., Giuliano, F., Ulbrich, E., Bandel, T. Int. J. Impot. Res. (2001)
- Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Porst, H. Int. J. Impot. Res. (2000)
